Potential COVID-19 vaccine passes important milestone
Since March, Attana has been assisting the team of Prof Ali Salanti at the University of Copenhagen in their development of a COVID-19 vaccine together with the Prevent-nCov consortium. Their vaccine is based on the Capsid Virus-Like Particle (cVLP) technology where coronavirus antigens are attached to the cVLP allowing the body’s immune system to respond to the antigens and produce antibodies.During the past two months the vaccine has been tested in mice which produced large amounts of antibodies able to neutralize SARS-CoV-2 virus and the response was several hundred times stronger than